In 2009, the humanized monoclonal antibody bevacizumab targeting tumor angiogenesis (through the vascular endothelial growth factor (VEGF)), was approved for the treatment of recurrent glioblastoma patients on the basis of its ability to achieve superior progression-free survival (PFS), yet in the lamentable absence of meaningful overall survival (OS) improvement [7]. Here, VEGFA is linked to neoplasm.